DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study
The DecisionDx-Melanoma gene expression assay (test) evaluates the genetic makeup of tumor tissue and classifies it as low risk (Class 1) or high risk (Class 2) for spreading to other areas of the body. This study is being done to collect information about how physicians are using the DecisionDx-Melanoma results to design individual treatment plans.
Cutaneous melanoma (melanoma of the skin)
1. Newly diagnosed stage I-III cutaneous melanoma patients for whom the physician has determined the DecisionDx-Melanoma test to be medically necessary for treatment management guidance.
2. Male and female patients > 18 Years of age.
3. Patient must speak and read English and be able to give informed consent.
Other criteria may apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Patients will visit their physician as often as he/she feels necessary for routine care. There are no study-related visits required. Participation in the study will last up to 6 months.
Knight Clinical Trials
Castle Biosciences, Inc.